Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
- Status
- COMPLETED
- Phase
- PHASE2
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Bortezomib in Patients With Chronic Graft Versus Host Disease
- Status
- COMPLETED
- Phase
- PHASE1
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
- Status
- WITHDRAWN
- Phase
- PHASE2
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Autophagy Induction After Bortezomib for Myeloma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Randomised Trial in Waldenstrom's Macroglobulinaemia
- Status
- COMPLETED
- Phase
- PHASE2
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
- Status
- TERMINATED
- Phase
- PHASE2
Velcade (Bortezomib) Consolidation After Transplant
- Status
- COMPLETED
- Phase
- PHASE3
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2